Speaker(s): 

Gurmukteshwar Singh, MD - Geisinger staff has nothing to disclose
Alex Chang, MD - Geisinger Staff has listed the following disclosures: Consulting: Novartis, Reata, Amgen, Relypsa, Research Funding: Novartis, Novo Nordisk, The National Kidney Foundation
Income: Medscape
 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

  • Identify Hospital-associated AKI as a strong marker of short and intermediate-term readmission and mortality
  • Describe system-level interventions in place to improve outcomes of high-risk AKI patients
  • Explain the role of face-to-face and non-face-to-face interventions and importance of a multidisciplinary team in management of complex AKI patients and hypertension patients

 

The Planning Committee consisting of Stefanie Leader, DO; Stanley Martin, MD; Dan Dometita, DO; Malachi Courtney, MD; Eric Hossler, DO; Stacey Coolbaugh, RDN; and Donald Wieder, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

CE Committee Reviewers: Natalie Stinton, DMD, and Courtney Hugo, MEd, MS; have nothing to disclose. 

Session date: 
03/01/2024 - 12:30pm to 1:30pm EST
Location: 
Microsoft Teams Meeting
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 CDR
  • 1.00 Participation Credit

Please login or register to take this course.